全文获取类型
收费全文 | 178133篇 |
免费 | 47090篇 |
国内免费 | 2614篇 |
专业分类
耳鼻咽喉 | 2072篇 |
儿科学 | 5998篇 |
妇产科学 | 1483篇 |
基础医学 | 35228篇 |
口腔科学 | 7459篇 |
临床医学 | 17620篇 |
内科学 | 36733篇 |
皮肤病学 | 5274篇 |
神经病学 | 27728篇 |
特种医学 | 6702篇 |
外国民族医学 | 20篇 |
外科学 | 18915篇 |
综合类 | 7803篇 |
现状与发展 | 8篇 |
一般理论 | 8篇 |
预防医学 | 9525篇 |
眼科学 | 1955篇 |
药学 | 22145篇 |
5篇 | |
中国医学 | 3163篇 |
肿瘤学 | 17993篇 |
出版年
2024年 | 95篇 |
2023年 | 805篇 |
2022年 | 1444篇 |
2021年 | 3651篇 |
2020年 | 7669篇 |
2019年 | 12897篇 |
2018年 | 12546篇 |
2017年 | 13762篇 |
2016年 | 12932篇 |
2015年 | 13201篇 |
2014年 | 14431篇 |
2013年 | 15909篇 |
2012年 | 13823篇 |
2011年 | 14323篇 |
2010年 | 12310篇 |
2009年 | 8993篇 |
2008年 | 9858篇 |
2007年 | 7945篇 |
2006年 | 7258篇 |
2005年 | 6591篇 |
2004年 | 6306篇 |
2003年 | 5774篇 |
2002年 | 5129篇 |
2001年 | 4097篇 |
2000年 | 2851篇 |
1999年 | 1564篇 |
1998年 | 1537篇 |
1997年 | 1430篇 |
1996年 | 1303篇 |
1995年 | 1026篇 |
1994年 | 932篇 |
1993年 | 837篇 |
1992年 | 630篇 |
1991年 | 597篇 |
1990年 | 442篇 |
1989年 | 365篇 |
1988年 | 309篇 |
1987年 | 280篇 |
1986年 | 296篇 |
1985年 | 360篇 |
1984年 | 295篇 |
1983年 | 181篇 |
1982年 | 242篇 |
1981年 | 193篇 |
1980年 | 137篇 |
1979年 | 83篇 |
1978年 | 56篇 |
1977年 | 45篇 |
1976年 | 32篇 |
1975年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
2.
3.
4.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
5.
目的 探讨溶质载体蛋白(SLC)及其受体趋化因子受体7(CCR7)与I期非小细胞肺癌(NSCLC)淋巴结微转移的相关性。方法 选取2019年1月~2020年3月于我院就诊的I期NSCLC患者127例为研究对象,按照淋巴结微转移情况分为对照组92例和转移组35例,所有患者入院后均通过根治术切除病灶,通过免疫组化方式检测病灶中SLC7A11及CCR7含量,并收集患者临床资料、实验室检查资料及影像学检查资料。通过Logistic回归分析评价SLC7A11及CCR7与淋巴结微转移之间的关系。最后通过建立ROC曲线分析两者及其联合检测对NSCLC患者微淋巴结转移的预测价值。结果 两组患者SLC7A11及CCR7表达水平存在显著差异(P<0.05)。转移组患者病灶直径、支气管受累及TLG显著高于对照组(P<0.05)。病灶直径(OR=49.254,95%CI=11.062~507.604)是影响NSCLC淋巴结微转移的独立危险因素(P<0.05)。SLC7A11(OR=8.622)及CCR7(OR=8.709)表达水平是影响NSCLC淋巴结微转移的独立因素(P<0.05)。SLC7A11、CCR7及联合诊断对NSCLC淋巴结微转移具有较好的检测价值(均P<0.05)。联合检测特异度显著高于 SLC7A11及CCR7单独检测(2=7.292,15.125;均P<0.01)。结论 SLC家族的中SLC7A11及其受体CCR7与NSCLC患者微淋巴结转移显著相关。 相似文献
6.
《Value in health》2022,25(6):1010-1017
ObjectivesSurvival extrapolation for chimeric antigen receptor T-cell therapies is challenging, owing to their unique mechanistic properties that translate to complex hazard functions. Axicabtagene ciloleucel is indicated for the treatment of relapse or refractory diffuse large B-cell lymphoma after 2 or more lines of therapy based on the ZUMA-1 trial. Four data snapshots are available, with minimum follow-up of 12, 24, 36, and 48 months. This analysis explores how survival extrapolations for axicabtagene ciloleucel using ZUMA-1 data can be validated and compared.MethodsThree different parametric modeling approaches were applied: standard parametric, spline-based, and cure-based models. Models were compared using a range of metrics, across the 4 data snapshot, including visual fit, plausibility of long-term estimates, statistical goodness of fit, inspection of hazard plots, point-estimate accuracy, and conditional survival estimates.ResultsStandard and spline-based parametric extrapolations were generally incapable of fitting the ZUMA-1 data well. Cure-based models provided the best fit based on the earliest data snapshot, with extrapolations remaining consistent as data matured. At 48 months, the maximum survival overestimate was 8.3% (Gompertz mixture-cure model) versus the maximum underestimate of 33.5% (Weibull standard parametric model).ConclusionsWhere a plateau in the survival curve is clinically plausible, cure-based models may be helpful in making accurate predictions based on immature data. The ability to reliably extrapolate from maturing data may reduce delays in patient access to potentially lifesaving treatments. Additional research is required to understand how models compare in broader contexts, including different treatments and therapeutic areas. 相似文献
7.
Phoebe Hammer Kevin White Stephanie Mengden Vessy Korcheva Philipp W. Raess 《Journal of cutaneous pathology》2019,46(5):343-346
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances. 相似文献
8.
Keiko Goto Yutaka Fujiwara Takeshi Isobe Naoko Chayahara Naomi Kiyota Toru Mukohara Yukari Tsubata Takamasa Hotta Kenji Tamura Noboru Yamamoto Hironobu Minami 《Cancer science》2019,110(6):1987-1994
Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S‐1 in patients with renal impairment. We classified patients receiving S‐1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S‐1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m2), 10 patients in cohort 2 (eGFR = 50‐79 mL/min/1.73 m2), 10 patients in cohort 3 (eGFR = 30‐49 mL/min/1.73 m2), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m2). Those in cohorts 3 and 4 treated with an adjusted dose of S‐1 showed a similar area under the curve for 5‐fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S‐1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S‐1 in patients with impaired renal function using eGFR is appropriate and safe. 相似文献
9.